Skip to main content
Premium Trial:

Request an Annual Quote

BioSeek to Collaborate with Ono

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Predictive biology company BioSeek said today that it will collaborate with Ono Pharmaceutical in a drug target screening collaboration.

Under a three-year agreement, BioSeek will use its BioMap platform in a collaboration that will focus on a specific drug target class designated by Ono.

BioSeek will use the Biomap to perform phenotypic screening and hit identification, lead optimization, and clinical candidate selection. For its efforts, BioSeek, which is a subsidiary of Asterand, will receive research funding and a milestone payment linked to development of the Ono drug candidate.

Osaka, Japan-based Ono will have the worldwide rights to develop and sell any pharmaceutical products discovered through the collaboration.

The BioMap systems use cell-based models of pathway interactions to understand toxicological properties of compounds including target effects, dose responses, and the discrimination of related compounds.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.